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Abstract Neuronal nicotinic acetylcholine receptors are a
prototype of ligand-gated channels that mediate transmission in
the central and peripheral nervous system. Structure^function
studies performed at the amino acid level are now unraveling the
determinant residues either for the properties of the ligand-
binding domain or the ionic pore. In this work we review,
in the light of the latest finding, the structure^function relation-
ship of these receptors and their implication in neurological
diseases. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
First characterisation of the neurotransmission soon re-
vealed the discontinuity of the electrical signal propagation
and suggested the existence of a chemical compound that
mediated transmission between neurones, or neurones and
the e¡ector cells. Acetylcholine (ACh) was the ¢rst identi¢ed
neurotransmitter by the classical O. Loewi experiments on the
heart muscle cells. Since then, it was demonstrated that chol-
inergic transmission could be divided in two groups according
to the pharmacological sensitivity to muscarine or nicotine.
Best studied at the vertebrate neuromuscular junction and in
the ¢sh electrical organ, nicotinic acetylcholine receptors
(nAChRs) have been, for a long time, a model of ligand-gated
channels.
Initial studies carried out at the neuromuscular junction
have revealed that the nAChRs result from the assembly of
¢ve subunits in a pentamer with the stoichiometry K2,L,Q,N [1].
This subunit composition corresponds to the Torpedo electri-
cal organ or the embryonic neuromuscular junction receptor.
When the endplate is innervated in the adult form, the Q sub-
unit is replaced by the O subunit. Forming both the ligand-
binding site and the channel domain, assembly of these sub-
units was shown to faithfully reproduce the properties of the
endplate receptor in reconstitution systems [2,3]. Paving the
road to structure^function experiments these, initial studies
have illustrated the importance of the correlation that exists
between the amino acid residues and the receptor properties.
Given the strong dependence on nicotine intake, as seen for
instance in tobacco smoke, it was supposed that nicotine ef-
fects should not be restricted to the neuromuscular junction
endplate, but should also a¡ect the central nervous system.
Although it was shown that nAChRs mediate neurotransmis-
sion in ganglia, their existence and structure in the central
nervous system remained elusive.
Following the identi¢cation of the genes encoding the neu-
romuscular receptor subunits, the cloning with low stringency
soon revealed that sequences homologous to those of the
muscle could be identi¢ed [4^6]. Mapping the expression of
these homologous subunits revealed that they are expressed in
the central nervous system [7^12]. So far, in vertebrate tissues,
12 nicotinic receptor subunits (K2^10; L2^4) have been cloned
[12^14]
The identi¢cation of the neuronal nAChR genes gave a new
and important impetus to the studies of neurotransmission.
Interest in this ¢eld was further reinforced with the observa-
tion of the positive cognitive e¡ects caused by nicotine, and
the correlation existing between neurological diseases and the
nAChRs (review in [15]).
In this work we focused on the neuronal nAChRs that are
expressed in the central and peripheral nervous system with
special attention on the structure^function relationship.
2. nAChR: pentameric glycoprotein
Historically, the nAChRs expressed by vertebrate neuro-
muscular junction and Torpedo marmorata or electrical eel
organs were the ¢rst characterised. Because these tissues al-
lowed extraction of a large fraction of highly rich receptors,
these biological sources opened the way to biochemical experi-
ments, and so, became the model of the nicotinic receptor
investigations.
During the 1970s, the puri¢cation of the receptors from
these tissues de¢ned a glycoprotein of 290 kDa. The protein
was then dissociated, using the SDS detergent technique, into
four di¡erent types of subunits named K, L, Q and N according
to their increasing molecular weights (reviewed in [1]). Addi-
tional subdivision between subunits was made according to
the presence of a cysteine doublet that was thought to partic-
ipate in the ACh-binding site. Thus, when presenting two
adjacent cysteines in their N-terminal part, muscle and neuro-
nal subunits were classi¢ed in the K subunit group. To date,
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nine K (K2^K10) and three L (L2^L4) neuronal subunits encod-
ing the nAChRs have been cloned [12,16].
Plot of the hydrophobicity of nAChR subunits revealed
that they all presented four hydrophobic segments that were
thought to form the transmembrane domains (TMI^TMIV).
Other hallmarks are the long N-terminal extracellular part
presenting glycosylation sites, a large intracellular domain
(100^200 amino acids) between TMIII and TMIV presenting
phosphorylation sites, and a short C-terminal domain (4^28
amino acids). The N-terminal hydrophilic part contains a di-
sulphide-linked loop. The intracellular loop, comprised be-
tween the TMIII and TMIV segments, contains putative
phosphorylation sites [17,18].
3. Receptor localisation
Mapping of the nAChRs in the brain yielded surprising
results. It was observed that receptors are widely distributed,
but that some receptors seem principally localised on terminal
boutons. The emerging ¢gure of nAChR subcellular pattern
of localisation indicates a concentration of receptors on post-
synaptic, presynaptic or even axonic areas [19,20]. In the view
of the high calcium permeability of the neuronal nAChRs,
di¡erent e¡ects were predicted depending upon this subcellu-
lar localisation. Moreover, it is now widely documented that
nAChRs can cause a signi¢cant calcium in£ux in the presyn-
aptic bouton, and therefore modulate the neurotransmitter
release [19^26]. In£uence of the nAChRs on dopamine, glu-
tamate, serotonin and GABA release was illustrated both in
biochemical and electrophysiological experiments. For exam-
ple, it is supposed that nicotine addiction is mediated by the
in£uence of nAChRs on the dopamine release in the meso-
lymbic pathways. Experiments carried out with L2 knock-out
mice have shown that these animals display a lower addiction
to nicotine than their wild-type siblings [27]. These last studies
justify the correlation between the nature of nAChR subtypes
with their localisation.
4. Stoichiometry
While subunit composition at the neuromuscular receptors
was established rather early, less was known concerning the
neuronal nAChR composition. The minute amount of biolog-
ical material renders biochemical experiments di⁄cult, and
putative stoichiometry must be derived from an ensemble of
converging information. First, and as for the muscle receptor,
the molecular weight of puri¢ed nAChRs is always in the 300
kDa range [28]. Since all subunits identi¢ed so far are less
than 600 aa in length, every subunit is expected to weight
approximately 40^70 kDa. Thus, neuronal nAChRs are ex-
pected to result from the assembly of ¢ve subunits. Immuno-
precipitations, using antibodies directed against subunit spe-
ci¢c epitopes, and in situ hybridisation indicate that the
ganglionic receptors probably result from the assembly of
K3 and L4 subunits, while the major brain receptor must
contain K4 and L2 subunits [28,29]. Expression and identi¢ca-
tion of a small amount of the K5 subunit suggest that this
subunit may further participate in the formation of a fraction
of receptors [30]. Additional evidence indicate that alternative
receptor assemblies, including K3 and L2 or other subunits,
are also present in the central nervous system [31,32]. While it
was clearly shown that many receptors result from heteromer-
ic assembly of two or more distinct subunits, it was also
shown that a fraction of the receptors are homomeric
[16,33^36].
Reconstitution experiments performed in host systems such
as Xenopus laevis oocytes and/or transfection in cell lines have
clearly demonstrated that functional nAChRs can be obtained
by expression of at least two subunits for heteromeric recep-
tors (i.e. K4 and L2) and a single subunit for homomeric
receptors (i.e. K7) [4^6,34,35,37^39]. In addition, combination
of site-directed mutagenesis and single-channel studies have
demonstrated the pentameric structure of K4L2 nAChRs, in-
dicating that they are composed of two K4 and three L2 sub-
units [40]. Furthermore, it was reported that homomeric K7
receptors display ¢ve binding sites for the competitive antag-
onist methyllycaconitine, and therefore must also be pentame-
ric [41]. The most recent report of the crystalline structure of
the acetylcholine-binding protein (ACh-BP) isolated from
snails further con¢rms the pentameric organisation of the
N-terminal domain [42].
5. Binding site
The reconstitution of functional receptors isolated by bio-
chemical puri¢cation of proteins from Torpedo electric organ
constituted the ¢rst demonstration that these proteins can
form both the ligand-binding site and the ionic pore. From
investigations in the 1980s on the kinetics of ionic current
through the single channel, it has been accepted that two
agonist-binding sites exist. The occupancy of these two sites,
in a positive cooperative way, stabilise the receptor channel in
the open state [43^46]. Using the method of the £uorescence
resonance energy transfer, between a receptor-bound £uores-
cent agonist and two membrane-£uorescent probes, the ACh-
binding sites were estimated to be 25 Aî below the extracellular
apex of the nAChR. Later, high-resolution electron microsco-
py technique results were in agreement with the proposed
location for the ACh-binding sites in putative ‘pockets’, at
each of two K subunits in the pentameric receptor, and ap-
proximately 30 Aî above the membrane surface [47^50].
With the availability of speci¢c chemical compounds and
the amino acid sequences of the di¡erent nAChR subunits,
important advances concerning our knowledge of the ACh-
binding site have been made. For instance, photoa⁄nity ex-
periments carried out with the muscle-type receptor have
shown that the ligand-binding site must be at the interface
between the Ks and their adjacent Q or N subunits (Fig. 1)
[51^54].
Six loops termed A^F have been identi¢ed in the formation
of the ACh-binding site. The K subunit, which harbours the
principal component of the binding site, comprises the A, B
and C loops, while the complementary component of the ad-
jacent subunit (Q, N or O for the muscle and L for the neuronal)
comprises the D, E and F loops (Fig. 1). The important par-
ticipation of tyrosine residues to the ACh-binding pocket has
been identi¢ed by the combination of site-directed mutagene-
sis and electrophysiological investigation of the chick K7 re-
ceptor subtype [55]. Modelling of the putative three-dimen-
sional structure of the nAChRs [56,57] all con¢rmed that
the ACh-binding site must reside at the interface between
two subunits and that the ligand must penetrate into a gorge
to form appropriate chemical bridges and initiate the trans-
duction. Modelling of the extracellular domains with the
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known crystal structure of the copper-binding proteins was
also attempted [58]. The very recent identi¢cation of ACh-
BP, a molecule that e⁄ciently binds ACh and that is secreted
from the glial cells of snails, allowed the ¢rst crystallisation of
a protein that resembles the N-terminal domain of the
nAChRs. X-ray di¡raction analysis of this structure con-
¢rmed the predictions made from the various models and
the existence of the A, B, C, D and E loops in the formation
of the binding pocket [42]. This crystal structure reveals two
L sheet skeletons forming the gorge in which the ACh enters
and binds to speci¢c residues (Fig. 1D).
6. Receptor pharmacology
In the early work carried out at the neuromuscular junction
and at ganglionic receptors, it was shown that signi¢cant
pharmacological di¡erences exist between these receptor sub-
types. A major criteria initially used was the di¡erence in
sensitivity to the snake toxin K-bungarotoxin (K-Bgt) [59]. It
was shown in reconstitution experiments that homomeric re-
ceptors K7, K8 and K9 are blocked by K-Bgt, whereas hetero-
meric receptors are insensitive to this toxin [16,34^36,60]. This
observation shed new light in the understanding of the exis-
tence of a strong K-Bgt labelling in the rat brain [61]. Thus, it
was postulated that K7-containing receptors must be ex-
pressed in the central nervous system and could participate
in the neurotransmission. While the existence of homomeric
K7 receptors in the brain was, for a long time, a matter of
debate, a clear biochemical demonstration of the presence of
such receptors was obtained from rat brain [62].
Fig. 1. Schematic representation of the nAChR. A: Heteropentameric complex of neuronal nicotinic K and L subunits (note the 2:3 ratio be-
tween the K and L). The ACh-binding site is localised at the interface of K and the adjacent subunit. B: Representation of the principal compo-
nent (K subunit) with its three loops A, B, C and the two loops D, E from the complementary component (L subunit). Each loop is schema-
tised with the principal amino acids identi¢ed at the chick K7 subunit. The E loop was shown to participate in the Ca2-binding region
involved in the calcium potentiation. C: Side view of the topological pentameric organisation of subunits through the cell membrane with the
schematic drawing of the four transmembrane domains (TMI^TMIV). D: Three-dimensional representation of the protein folding derived from
the ACh-BP crystal (redrawn from [42]). The interface of two adjacent subunits showing more particularly the disulphide bridge of the C loop
involved in the ACh-binding site.
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Because the ACh-binding site is at the interface between
two adjacent subunits, it is evident that both must contribute
to the binding-site properties. This is clearly illustrated when
examining the ACh properties of di¡erent receptor combina-
tions (Fig. 2). Exchange of K or L subunits causes marked
changes at the current desensitisation and/or at the apparent
ACh sensitivity. While discussion of the pharmacological
properties of the nAChRs would require an entire review
per se, it is interesting to note that nicotine versus ACh sensi-
tivity could be distinguished using microchimeric construc-
tions [63]. Bringing further insights in the understanding of
the ACh-binding pocket, these experiments have again illus-
trated the importance of the A^E loops (Fig. 1).
7. Channel structure and permeability
The nAChRs belong to the superfamily of four transmem-
brane ligand-gated proteins, including Q-aminobutyric acid
(GABAA, GABAC), glycine receptors (glyR), serotonin (5-hy-
droxytryptamine (5HT3)) and the chloride permeable gluta-
mate receptors (GluRCl). In addition to structural homologies
with these receptors, the nAChRs display the same basic func-
tional properties. Namely, upon binding of a speci¢c neuro-
transmitter, the channel is quickly opened and ions freely
di¡use following their gradient, and thereby mediate synaptic
transmission. Fundamental di¡erences exist, however, in the
ionic selectivity between cationic (nAChRs, 5HT3) and
anionic (GABAA, GABAC, glyR and GluRCl) permeable
channels. In this section we shall review our knowledge about
the mechanisms underlying the ionic selectivity of the
nAChRs.
Electrophysiological and biochemical measurements per-
formed at the neuromuscular junction nAChRs have shown
that these receptors are permeable to monovalent cations, but
display a rather low permeability to divalent cations. Mea-
surements of the current^voltage relationship showed un-
equivocally that these receptors follow the Ohms law with
the current amplitude being proportional to the electrical ¢eld
applied across the membrane. Estimated by the displacement
of the reversal potential in relation to the extracellular ionic
composition, these channels display a pore size of about 6 Aî
[64,65] (reviewed in [66]). In contrast, neuronal nAChRs dis-
play two marked characteristics : (a) a strong voltage depend-
ency (inward recti¢cation) and (b) a large permeability to
calcium [34,67^71]. Inward recti¢cation and the high calcium
permeability have been con¢rmed in both reconstituted and
native receptors [72,73].
To better understand the properties of ligand-gated chan-
nels, and in particular of the nAChRs, it is necessary to ex-
amine the structure of the ionic pore. Initially, the channel
structure was investigated by photolabelling using the open-
channel blocker termed chlorpromazine. From the labelling of
the second transmembrane segment of the four di¡erent sub-
units (K, L, Q, N), it was concluded that this segment must form
the wall of the ionic pore, and therefore de¢nes its biophysical
properties [74^76]. Indeed, it was soon con¢rmed that site-
directed mutagenesis of amino acid residues at the inner or
outer mouth of this putative aqueous pore had a signi¢cant
e¡ect on the ionic selectivity of the channel [2]. For instance,
it must be recalled that, at the muscle receptor, mutation of a
single amino acid within TMII was enough to reduce the in-
hibition caused by the lidocaine derivative QX-222 [77,78].
Another prediction derived from the chlorpromazine labelling
is that TMII must form an K-helix. Modelling, derived either
from sequence alignments or minimal energy computations,
has supported this K-helix arrangement [56,58,79,80], as has
high-resolution electron microscopy [48,50,81].
The identi¢cation of the homomeric K7 nAChR [35] per-
mitted a simpli¢cation of the structure^function relationship
studies. In these nAChRs, mutation of a single amino acid is
enough to perform the mutation of the entire rings that con-
¢ne the ionic pore. Using this protein as a prototype of li-
gand-gated channels, numerous ¢ndings have been made. Mu-
tation of the chlorpromazine-labelled leucine residue that is
conserved throughout the di¡erent nAChRs (chick K7 L247)
caused marked and unexpected modi¢cation of the receptor
functional properties. For instance, mutation L247T causes an
increase of about 200-fold in ACh sensitivity, loss of desensi-
tisation and changes in pharmacological pro¢le with the com-
petitive antagonists becoming agonists [82,83].
To understand the critical role played by this ‘canonical’
leucine residue, which is conserved throughout cationic and
anionic receptors, it is necessary to recall the general putative
topology of the channel. Presenting a wide opening of about
25 Aî in the extracellular domain, the channel progressively
becomes narrower and forms a constriction to become wider
again in the intracellular domain (see Fig. 1). High-resolution
electron microscopy images suggest that the L247 residue
must be close to the selectivity ¢lter, in a section of the chan-
nel that should display high conformation £exibility [50]. The
Fig. 2. Properties of the nAChRs are de¢ned both by K and L sub-
units. Oocytes injected with di¡erent cDNA combinations were chal-
lenged with ACh in the voltage^clamp con¢guration. Cells were
held at 3100 mV and currents evoked by series of ACh concentra-
tions were recorded and superimposed. Subunit composition is sche-
matised on the top of each set of traces.
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best explanation of the pleiotropic e¡ects caused by the
L247T mutation was proposed in the early work from Revah
and collaborators who concluded that this mutation renders
conductor one of the desensitised states. Thus, any action that
stabilises the receptor in this desensitised state will evoke an
inward current. Several predictions can be made from this
proposition. For instance, at rest, it is known that a fraction
of the receptor is in the desensitised state [1], thus it was
predicted that the L247T mutant should display spontane-
ously open channels. This prediction was later con¢rmed in
the chick K7 receptor [84]. Whereas it is not in the scope of
this review to examine, in detail, all e¡ects caused by this
mutation, it is important to recall that similar ¢ndings were
made for 5HT3, muscle nAChR, heteromeric nAChRs and
GABAA [85^87].
7.1. Ionic selectivity
Determinants of ionic selectivity ¢lter were analysed either
by site-directed mutagenesis, designed on the basis of se-
quence comparison (i.e. [88]), or by cysteine scanning using
cysteine-reactive probes (i.e. [89,90]). Cysteine scanning ex-
periments have revealed that, in agreement with the putative
K-helix structure, substitutions of the amino acid residues
pointing toward the pore lumen render the channel sensitive
to test reagents. In contrast, no reaction was observed when
the mutations were e¡ectuated at amino acids that were not
supposed to face the pore [90]. The di¡erence in blockade
observed when the reagent was introduced from the extracel-
lular or intracellular compartment was interpreted by these
authors as re£ecting a constriction of the channel in the vi-
cinity of the intracellular mouth.
Sequence analyses of consensus amino acid residues facing
the ionic pore between the di¡erent members of the four
transmembrane domain ligand-gated channels revealed a
striking homology, even between cationic and anionic chan-
nels. In view of this homology, substitution of the chick K7
residues with those found in GABAA or glyR was attempted.
The power of this approach was shown with the conversion of
the ionic selectivity of the chick K7 from cationic to anionic
[88]. Moreover, in subsequent work, amino acids responsible
for this ionic conversion were further analysed in more detail
[91,92]. From these experiments, it was concluded that some
amino acids were permissive, but that introduction of a pro-
line or alanine residue between the inner and intermediate
rings (see Figs. 1 and 3) was indispensable for the conversion
of the ionic selectivity. The basic principle underlying this
ionic selectivity was further reinforced when determinant ami-
no acids, proposed by Galzi et al., were mutated in the glyR
and caused the conversion from anionic to cationic [93].
7.2. Calcium permeability and recti¢cation
The chick K7 nAChR, highly permeable to calcium, can
have the calcium permeation abolished with the exchange of
a single amino acid residue in the second transmembrane do-
main [68]. It was shown that removal of a charged residue at
the intermediate ring (E237, in the chick numbering) is su⁄-
cient to abolish the calcium permeability without signi¢cantly
changing the ratio PK/PNa permeability. A second site was
identi¢ed at the level of two adjacent leucines (L254 and
L255), where mutation of either of these leucines into a threo-
nine was su⁄cient to suppress calcium permeability. Interest-
ingly, while a charged residue seems necessary at the inter-
mediate ring for the calcium permeability, another mechanism
must apply in the upper channel domain. Shortening of the
lateral side chain is su⁄cient to prevent the calcium in£ux,
apparently without modifying the monovalent cations perme-
ation.
While most of site-directed mutagenesis experiments have
been performed at the homomeric K7 receptor, basic princi-
ples involved in ionic selectivity have been veri¢ed on hetero-
meric receptors. The contribution of charged residues at the
intermediate ring was also found to be determinant for the
calcium permeability of the heteromeric K3L4 and K4L2 re-
ceptors [94]. Less permeable to calcium than the K7 receptor,
these heteromeric receptors are equally a¡ected by the substi-
tution residue at the intermediate ring of the glutamate by an
alanine, and removal of this charged residue a¡ects both rec-
ti¢cation and calcium permeability.
8. Conservation of functional domains
The identi¢cation of a large homology, and even identity
between the members of the superfamily of four transmem-
brane ligand-gated channels, suggests that these receptors may
have evolved from a common ancestor gene by duplication
and selection. Developed by several authors [56], this concept
implies that functional domains may have been conserved
between the di¡erent members of the superfamily.
As a challenge to this hypothesis it was proposed that chi-
mera may be produced either between members of a given
receptor type (i.e. nAChRs) or even across near-by ‘cousin’
receptors (i.e. nAChRs and 5HT3). Constructions of micro-
chimeras between di¡erent nAChR subunits represent an im-
portant tool for the investigation of a given subunit property.
For instance, it was shown that homomerisation, which is a
key feature of the K7 receptor, can be transmitted to chimeras
constructed with the K3 subunit [95]. A further extension of
this concept was demonstrated with the construction of a
functional chimera between the K7 and 5HT3 receptor sub-
units [96]. Properties of this chimeric receptor are those of the
K7 receptor with the ACh-recognition and -binding site,
whereas the channel domain displays the properties of the
5HT3 receptor. Interestingly, it was later shown that the
muscle K1 subunit can also be fused with the 5HT3 receptor,
and resulted in a protein able to bind K-Bgt. Binding proper-
ties are conserved in this receptor, but nicotine or ACh failed
to elicit current, indicating a lack of functional properties.
Fig. 3. Putative representation of the TMII segment in the pore-
forming region. Wild-type amino acid and putative con¢guration is
schematised in the left panel. The anionic permeable channel ob-
tained by mutation of V251T, E237A and the proline insertion is
represented in the right panel. Amino acids are indicated by their
single-letter code and positions refer to the chick K7 numbering
[88,92].
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Since this initial work, a number of fusion proteins and
further microchimerisation have been utilized to explore the
microdomains of a given receptor.
9. nAChR: a prototype of allosteric protein
As an extension of their work, Changeux and co-workers
introduced the concept that ligand-gated channels behave as
an allosteric protein with multiple possible conformations
[97]. According to the allosteric model, the receptor can spon-
taneously change state in the absence of ligand. Although any
transition can occur, probability of channel opening is ex-
tremely low. Exposure to the neurotransmitter preferentially
stabilises the receptor in the open con¢guration. In contrast,
the induce ¢t model hypothesises that binding of the ligand
causes a conformational change of the protein but, unless
complex assumptions, no channel transition occurs in absence
of ligand.
The ‘multiple allosteric states’ are described as four discrete
B, A, I and D states. In the absence of an agonist the receptor
is principally stabilised in the resting B (closed) state. The
equilibrium constants are, however, such that a fraction of
the receptor is always in the desensitised D (closed) state.
At the neuromuscular junction, it was shown that approxi-
mately 20% of the receptors are in the desensitised state even
in absence of the agonist (reviewed in [1]). Binding of the
agonist preferentially stabilises the active A (open) state and
then subsequently the intermediate I (closed) state and pro-
gressively, but with a slower time constant, the desensitised D
(closed) state (see for review [63]). Interesting predictions de-
rived from the allosteric model are that transition from one
state to another can take place in the absence of ligand and
that compounds a¡ecting the transition constants can pro-
voke either a potentiation or an inhibition of the receptor.
While in normal conditions spontaneous opening probabil-
ity is extremely low at the neuromuscular junction [98], it was
shown that mutation of the ‘canonical’ leucine (L247) in the
chick K7 receptor was su⁄cient to cause channel opening in
the absence of agonist [84]. In addition, positive or negative
allosteric modulations of the receptors have been widely docu-
mented either for the homomeric K7 receptor [99] or the het-
eromeric K4L2 receptor [100,101]. Potentiation by extracellu-
lar calcium is indeed a good example of a positive allosteric
modulation that was analysed at the amino acid level [102].
The observation that extracellular calcium causes a marked
increase of the ACh-evoked current at the K7 nAChR, but
blocks the 5HT3 receptor, leads to the proposal that micro-
chimera construction should allow to identify the amino acid
segments involved in the calcium recognition site. Further-
more, analysis of the N-terminal of the K7 receptor suggests
the presence of calcium recognition elements near the ACh-
binding site. A putative EF motif (observed in calmodulin
proteins) was identi¢ed at the position 172 of the chick K7
receptor. Modi¢cation of these residues was shown to disrupt
calcium potentiation at the chick K7 receptor. As a correlate,
exchange of the corresponding 5HT3 receptor residues with
those of K7 was su⁄cient to confer the calcium potentiation
to the 5HT3 receptor [102]. Similarly, zinc modulation of het-
eromeric nAChRs showed that L4-containing receptors are
potentiated by low zinc concentration, whereas L2-containing
receptors were inhibited, and a putative zinc-binding sequence
was identi¢ed [101].
10. Conclusions
First demonstrated at the neuromuscular junction, nicotinic
receptors have been used for a long time as a model of the
chemical synaptic transmission. With the discovery that neu-
ronal nAChRs are widely expressed in the peripheral and
central nervous system, and with their modulatory role in
the neurotransmitter release, these receptors have received in-
creased attention. Further interest in this ¢eld was manifested
with the identi¢cation of associations between nAChRs and a
variety of neurological disorders including Parkinson, Alz-
heimer, schizophrenia, neurophatic pain or epilepsy. Linkage
between one form of genetically transmissible epilepsy and a
mutation in the gene encoding the K4 subunit of the nAChR
constituted the ¢rst important evidence for the contribution of
these ligand-gated channels in neuronal network dysfunction.
Characterisation of mechanisms and properties at the mo-
lecular level underlying neurotransmission is one of the major
challenges in today’s biology. The important knowledge of the
structure^function relationship of the nAChRs constitutes an
invaluable tool for the studies of the four transmembrane
domain ligand-gated channels family. The availability of a
¢rst crystal structure of the ACh-binding site is the latest
important step that shall allow the development of new and
better designed pharmaceutical compounds, and therefore
open new roads for clinical treatments.
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